UNI-EN 9:CORRECTION-Sales revenues for the first two months of 2017
Firma: SOPHARMA ADSpis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
|
| UNI - EN REPORT No | 9 | / | 2017 | |||||||
| Date of issue: | 2017-03-07 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| CORRECTION-Sales revenues for the first two months of 2017 | |||||||||||
| Official market - legal basis | |||||||||||
| art. 17. 1 MAR. | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| For the first two months of this year, revenues from sales increased by 8% compared to the same period of 2016, including 5% decrease of domestic sales and 16% increase of export sales. “We are very pleased with the results on the Russian market from the begining of this year and the trend is strenghteining in February reaching 40% increase in export sales. We are hopeful also with regards to the registration of our product Tabex in the USA. After the news about the merger of Achieve and OncoGenex the good news continue. You can read more abou the cooperation of Achieve with NIH here: www.oncogenex.com. The preliminary consolidated report of Sopharma Group for 2016 shows that even though the period was relatively difficult on our foreign markets, we still managed to reach a satisfactory EBITDA of 70 million BGN and a net profit of a little bit more than 50 million BGN. Analysis of the main indicators shows improved profitability due to optimization of main expenses and in the light of a maximum market price of a bit over 3 BGN for the year P/E is 8.31 and ROE is 10.9% compared to 5.3% for 2015.”, says Mr. Ognian Donev, PhD, CEO and Chairman of the Board of directors of Sopharma AD. | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| Sopharma monthly February 2017.doc Sopharma monthly February 2017.doc | CORRECTION-Sales revenues for the first two months of 2017 | ||||||||||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2017-03-07 | Ognian Donev | Executive director | |||
Cena akcji Sopharma
Cena akcji Sopharma w momencie publikacji komunikatu to 6.58 PLN. Sprawdź ile kosztuje akcja Sopharma aktualnie.
W tej sekcji znajdziesz wszystkie komunikaty ESPI EBI Sopharma.
